Sun Pharmaceutical today said its subsidiary has received approval from the US health regulator to market Bupropion Hydrochloride antidepressants tablets.
The US-based subsidiary of the company has received Food and Drug Administration approval to market its drug Bupropion Hydrochloride Bupropion Hydrochloride Extended-Release, Sun Pharmaceutical said in a filing to the Bombay Stock Exchange.
These tablets are available in strengths of 100 mg, 150 mg and 200 mg, the filing added.
Bupropion Hydrochloride Extended-Release tablets are used for the treatment of major depressive disorder.
These tablets are generic equivalent of GlaxoSmithKline's Wellbutrin SR tablets.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app